share_log
Reuters ·  Jul 9 06:32
60 Degrees Pharmaceuticals - Plans to File a New Drug Application With FDA in Q2 of 2026 for a Supplemental Indication for Tafenoquine in Babesiosis
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment